74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
AtriCure Inc
Closed
Sector Healthcare
38.3 -2.32
Overview
Share price change
24h
Min
38.2
Max
38.77
Income | -7.7M -16M |
|---|---|
Sales | 8.4M 124M |
EPS | -0.08 |
Profit margin | -12.527 |
Employees | 1,300 |
EBITDA | -8.8M -9.7M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +39.36 upside |
Next Earnings | 30 Apr 2025 |
|---|
Market Cap | -76M 1.9B |
|---|---|
Previous open | 40.62 |
Previous close | 38.3 |
News Sentiment
By Acuity
58%
42%
325 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
AtriCure Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
AtriCure Inc Forecast
Price Target
By TipRanks
39.36% upside
12 Months Forecast
Average 53.5 USD 39.36%
High 66 USD
Low 45 USD
Based on 8 Wall Street analysts offering 12 month price targets forAtriCure Inc - Dist in the last 3 months.
Sentiment
By Acuity
325 / 393 Healthcare
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About AtriCure Inc
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
